HC Wainwright Cuts Acelyrin (NASDAQ:SLRN) Price Target to $6.00

Acelyrin (NASDAQ:SLRN) had its price objective trimmed by HC Wainwright from $8.00 to $6.00 in a research report report published on Tuesday,Benzinga reports. They currently have a neutral rating on the stock. HC Wainwright also issued estimates for Acelyrin’s Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($2.60) EPS, FY2027 earnings at ($2.15) EPS, FY2028 earnings at ($1.58) EPS and FY2029 earnings at ($1.04) EPS.

Separately, Wells Fargo & Company lowered their price target on Acelyrin from $15.00 to $13.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, Acelyrin has an average rating of “Hold” and an average target price of $9.60.

Acelyrin Trading Down 2.7 %

NASDAQ SLRN opened at $2.14 on Tuesday. Acelyrin has a 1-year low of $1.91 and a 1-year high of $8.89. The stock’s 50 day moving average is $4.16 and its two-hundred day moving average is $4.84. The company has a market capitalization of $214.70 million, a price-to-earnings ratio of -0.87 and a beta of 1.94.

Institutional Investors Weigh In On Acelyrin

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company grew its holdings in shares of Acelyrin by 16.3% during the second quarter. The Manufacturers Life Insurance Company now owns 29,769 shares of the company’s stock worth $131,000 after purchasing an additional 4,163 shares during the last quarter. US Bancorp DE grew its holdings in Acelyrin by 77.1% during the 3rd quarter. US Bancorp DE now owns 16,854 shares of the company’s stock worth $83,000 after acquiring an additional 7,336 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Acelyrin by 65.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,196 shares of the company’s stock valued at $95,000 after acquiring an additional 7,560 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Acelyrin in the third quarter worth about $50,000. Finally, HighTower Advisors LLC acquired a new position in shares of Acelyrin during the third quarter worth approximately $50,000. 87.31% of the stock is owned by institutional investors and hedge funds.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.